Delivering Benefit to bone

Mesentech is a company  focused on treating diseases and medical conditions that relate to bone.
We are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.

Mesentech’s bone targeting technology allows for the development of multiple products across a wide-range of clinical conditions, from bone regeneration, to treatment of bone infections and cancers within bone.

BONE TARGETING TECHNOLOGY

Mesentech is developing a range of complementary approaches to clinical conditions affecting the bone.

&

BONE TARGETING

Delivery of small molecule drugs and growth factors directly to bone

  • Novel platform technology that can deliver enhanced efficacy and minimize side-effects
  • Effective targeting to bone confirmed in animal models
  • Developing products for – osteomyelitis, bone cancers and bone metastases

PRECLINICAL PROOF OF PRINCIPLE ACHIEVED

+

BONE REGENERATION

Both systemic and topical delivery

  • Pre-clinical utility confirmed in models of bone regeneration
  • Pre-clinical anabolic efficacy confirmed in models of osteoporosis
  • Developing dental and orthopaedic indications

PRECLINICAL PROOF OF PRINCIPLE ACHIEVED

/

GENE SILENCING

Nano-particle delivery of siRNA forgene knockdown

  • Developing silencing of bone-related genes (e.g. SOST) for osteoporosis and bone regeneration

IN RESEARCH